allogeneic natural killer cells

Phase 2Biologic

AActinium Pharmaceuticals

allogeneic natural killer cells is one of 153 biologic programs targeting Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

152

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Ovarian CancerActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Acute LeukemiaActive, not recruiting

MelanomaPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1/Phase 2

Active, not recruiting

Acute LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

CC 5013

Bristol-Myers Squibb

Phase 3

3 2

Actimmune

HHorizon Therapeutics Ireland DAC

Phase 3

—3

Systemic Chemotherapy

SSun Yat-sen University

Phase 3

1 4

Lymphoseek

NNavidea Biopharmaceuticals

Phase 3

1 5

Tumor Necrosis Factor

NNational Cancer Institute (NCI)

Phase 3

1 6

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 7

allogeneic natural killer cells

AActinium Pharmaceuticals

Phase 2

1 8

Intron a

Merck & Co.

Preclinical

4 9

Opdualag

Bristol-Myers Squibb

Preclinical

3 10

IO102-IO103

IIO Biotech

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2034

Phase 2/3Not yet recruiting

Refractory AML

NCT07157514

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00625729·6 enrolled

Ovarian Cancer1 trial

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00652899·14 enrolled

Melanoma1 trial

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00726739·21 enrolled

Refractory AML1 trial

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Not yet recruiting·AActinium Pharmaceuticals·Phase 2/3·NCT07157514·306 enrolled

Metastatic1 trial

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00784524·14 enrolled

3 more indications

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for allogeneic natural killer cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — allogeneic natural killer cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for allogeneic natural killer cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Actinium Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AActinium Pharmaceuticals

allogeneic natural killer cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2034

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

Ovarian Cancer1 trial

Melanoma1 trial

Refractory AML1 trial

Metastatic1 trial

Acute Leukemia1 trial

T Cells1 trial

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News